Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023
Immunic, Inc. (Nasdaq: IMUX) announced promising results from the open-label extension of its phase 2 EMPhASIS trial for vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS). Key findings show a low rate of confirmed disability worsening (CDW): only 1.6% in treatment arms versus 3.7% in placebo. After 48 weeks, 97.2% of patients were free from 12-week CDW. The data will be presented at ACTRIMS Forum 2023 in San Diego, highlighting vidofludimus calcium's potential against historical MS treatments. CEO Daniel Vitt expressed optimism about the ongoing phase 3 ENSURE program and phase 2 CALLIPER trial, set for data updates later this year.
- 1.6% confirmed disability worsening rate in treatment arms compared to 3.7% in placebo.
- 97.2% of patients were free from 12-week confirmed disability worsening after 48 weeks.
- Presentation at ACTRIMS Forum 2023 increases visibility for vidofludimus calcium.
- Ongoing phase 3 ENSURE program and phase 2 CALLIPER trial expected to provide further data.
- None.
– Long-Term Open-Label Treatment With Vidofludimus Calcium Was Associated With a Low Rate of Confirmed Disability Worsening (CDW) Over Time –
– CDW Data Compares Favorably to Historical Trial Data for Currently Available Multiple Sclerosis Treatments –
"The encouraging data from the 24-week double-blind main treatment period of the phase 2 EMPhASIS trial of vidofludimus calcium in RRMS patients showed that 12-week and 24-week Confirmed Disability Worsening (CDW) events occurred in
"The opportunity to present data from our EMPhASIS trial at the
Presentation Details:
- Abstract Number: 697
- Poster Title: Assessment of effect of vidofludimus calcium on MS progression in the blinded treatment and open-label extension periods of the phase 2 study (EMPhASIS) in relapsing-remitting multiple sclerosis
- Poster Number: P068
- Authors:
Robert J. Fox ,Christian Wolf ,Andreas Muehler ,Matej Ondrus ,Valentina Sciacca - Poster Session: Poster Session 1
- Date:
Thursday, February 23, 2023 - Time: 6:30 –
7:30 pm PT - Location:
Pacific Ballroom
The poster presentation will be accessible on the "Events and Presentations" section of
EMPhASIS is an international, multicenter, double-blind, placebo-controlled, randomized, parallel-group trial, designed to assess the efficacy and safety of vidofludimus calcium in patients with RRMS. The trial included a 24-week blinded main treatment period testing 10, 30 and 45 mg of vidofludimus calcium and placebo. In the third quarter of 2020,
The trial also includes an optional long-term OLE phase running up to 9.5 years. An interim analysis was performed with data extraction in
About Vidofludimus Calcium (IMU-838)
Vidofludimus calcium is an investigational drug in development as an orally available, next-generation selective immune modulator that is designed to inhibit the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase (DHODH). Vidofludimus calcium has been observed in preclinical studies to act on activated T and B cells while leaving other immune cells largely unaffected and allows the immune system to stay functioning, e.g., in fighting infections. In previous trials, vidofludimus calcium did not show an increased rate of infections compared to placebo. In addition, DHODH inhibitors, such as vidofludimus calcium, are known to possess a host-based antiviral effect, which is independent with respect to specific virus proteins and their structure. Therefore, DHODH inhibition may be broadly applicable against multiple viruses. To date, vidofludimus calcium has been tested in more than 1,100 individuals and has shown an attractive pharmacokinetic, safety and tolerability profile. Vidofludimus calcium is not yet licensed or approved in any country.
About
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash, expected timing and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to
Contact Information
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
+1 917 633 7790
immunic@rxir.com
US Media Contact
KOGS Communication
+1 617 974 8659
kaplan@kogspr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-presents-data-from-phase-2-emphasis-trial-of-vidofludimus-calcium-in-relapsing-remitting-multiple-sclerosis-at-actrims-forum-2023-301751746.html
SOURCE
FAQ
What are the results of the EMPhASIS trial for IMUX?
When will the data from the EMPhASIS trial be presented?
What is the significance of the confirmed disability worsening rates in the trial?